Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Calcineurin inhibition rescues alloantigen-specific central memory T cell subsets that promote chronic GVHD
Yewei Wang, … , Ping Zhang, Geoffrey R. Hill
Yewei Wang, … , Ping Zhang, Geoffrey R. Hill
Published June 3, 2024
Citation Information: J Clin Invest. 2024;134(11):e170125. https://doi.org/10.1172/JCI170125.
View: Text | PDF
Research Article Immunology

Calcineurin inhibition rescues alloantigen-specific central memory T cell subsets that promote chronic GVHD

  • Text
  • PDF
Abstract

Calcineurin inhibitors (CNIs) constitute the backbone of modern acute graft-versus-host disease (aGVHD) prophylaxis regimens but have limited efficacy in the prevention and treatment of chronic GVHD (cGVHD). We investigated the effect of CNIs on immune tolerance after stem cell transplantation with discovery-based single-cell gene expression and T cell receptor (TCR) assays of clonal immunity in tandem with traditional protein-based approaches and preclinical modeling. While cyclosporin and tacrolimus suppressed the clonal expansion of CD8+ T cells during GVHD, alloreactive CD4+ T cell clusters were preferentially expanded. Moreover, CNIs mediated reversible dose-dependent suppression of T cell activation and all stages of donor T cell exhaustion. Critically, CNIs promoted the expansion of both polyclonal and TCR-specific alloreactive central memory CD4+ T cells (TCM) with high self-renewal capacity that mediated cGVHD following drug withdrawal. In contrast to posttransplant cyclophosphamide (PT-Cy), CSA was ineffective in eliminating IL-17A–secreting alloreactive T cell clones that play an important role in the pathogenesis of cGVHD. Collectively, we have shown that, although CNIs attenuate aGVHD, they paradoxically rescue alloantigen-specific TCM, especially within the CD4+ compartment in lymphoid and GVHD target tissues, thus predisposing patients to cGVHD. These data provide further evidence to caution against CNI-based immune suppression without concurrent approaches that eliminate alloreactive T cell clones.

Authors

Yewei Wang, Md Ashik Ullah, Olivia G. Waltner, Shruti S. Bhise, Kathleen S. Ensbey, Christine R. Schmidt, Samuel R.W. Legg, Tomoko Sekiguchi, Ethan L. Nelson, Rachel D. Kuns, Nicole S. Nemychenkov, Erden Atilla, Albert C. Yeh, Shuichiro Takahashi, Julie R. Boiko, Antiopi Varelias, Bruce R. Blazar, Motoko Koyama, Simone A. Minnie, Andrew D. Clouston, Scott N. Furlan, Ping Zhang, Geoffrey R. Hill

×

Figure 1

CSA promotes the expansion of central memory donor T cells.

Options: View larger image (or click on image) Download as PowerPoint
CSA promotes the expansion of central memory donor T cells.
B6D2F1 recip...
B6D2F1 recipients were transplanted with B6 BM (5 × 106) + T cells (2 × 106) and treated with saline or CSA (5 mg/kg/d) up until day 13 after BMT. Spleens were taken 5 or 18 days after BMT and donor CD4+ and CD8+ T cells were analyzed (n = 10–15 per group from 2–3 experiments). (A) Frequency of donor T cells in viable cells and (B) absolute numbers per spleen. (C) Expression of T-bet in donor T cells. (D–H) Expression of cytokines in donor T cells were analyzed following intracellular cytokine staining: (D) UMAP plots of donor T cells on day 5 (concatenated from 5 samples per group), expression of (E) IFNγ, (F) TNF, (G) IL-17A, and (H) frequency and numbers of IFNγ+IL-10+ Tr1 cells. (I) Frequency and numbers of CD4+ FoxP3+ Tregs. (J–K) Composition of TN (CD44–CD62L+), TEM (CD44+CD62L–), and TCM (CD44+CD62L+) subsets in donor T cells on day 5 (J) and day 18 (K). Data are presented as median ± interquartile range and analyzed with the Mann-Whitney U test. *P < 0.05; **P < 0.01; ***P < 0.001.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts